Generic Medicine Info
Indications and Dosage
Chemotherapy-induced neutropenia
Adult: To reduce incidence of infection in patients with non-myeloid malignancies: 6 mg as a single dose for each chemotherapy cycle, given at least 24 hours after cytotoxic chemotherapy.
Incompatible w/ NaCl soln.
Special Precautions
Patient w/ sickle cell disease. Not intended for treatment of myelodysplastic syndrome, chronic myelogenous leukaemia and secondary acute myeloid leukaemia (AML). Pregnancy and lactation.
Adverse Reactions
Bone or musculoskeletal pain, hypersensitivity reactions (e.g. urticaria, skin rash, angioedema, erythema, flushing, dyspnoea, hypotension, cutaneous vasculitis, SC tissue disorders), splenomegaly, glomerulonephritis, leukocytosis, pulmonary AR (e.g. interstitial pneumonia; pulmonary oedema, infiltrates and fibrosis).
Potentially Fatal: Splenic rupture, resp failure or acute resp distress syndrome, capillary leak syndrome, serious allergic reactions (e.g. anaphylaxis), sickle cell crises (in patients w/ sickle cell disorders).
Monitoring Parameters
Obtain CBC w/ differential and platelet count prior to and during therapy. Monitor haematocrit regularly.
Drug Interactions
Diminished therapeutic effect w/ pegloticase.
Lab Interference
May interfere w/ bone imaging studies.
Mechanism of Action: Pegfilgrastim is a covalent conjugate of filgrastim and monomethoxypolyethylene glycol which binds to specific cell surface receptors of haematopoietic cells, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Absorption: Time to peak plasma concentration: 16-120 hr.
Excretion: Mainly via neutrophil-mediated clearance; serum clearance decreases w/ increasing dose. Half-life: 15-80 hr.
Store between 2-8°C. Do not freeze. Protect from light.
MIMS Class
Haematopoietic Agents
ATC Classification
L03AA13 - pegfilgrastim ; Belongs to the class of colony stimulating factors. Used as immunostimulants.
Anon. Pegfilgrastim. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 04/01/2016.

Buckingham R (ed). Filgrastim. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 04/01/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Pegfilgrastim. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 04/01/2016.

Neulasta Injection (Amgen Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 04/01/2016.

Neulasta Injection. U.S. FDA. Accessed 04/01/2016.

Disclaimer: This information is independently developed by MIMS based on Pegfilgrastim from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
  • Fulphila
  • Peglasta
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in